Literature DB >> 21166631

Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.

Athavudh Deesomchok1, Katherine A Webb, Lutz Forkert, Yuk-Miu Lam, Dror Ofir, Dennis Jensen, Denis E O'Donnell.   

Abstract

The natural history of lung hyperinflation in patients with airway obstruction is unknown. In particular, little information exists about the extent of air trapping and its reversibility to bronchodilator therapy in those with mild airway obstruction. We completed a retrospective analysis of data from individuals with airway obstruction who attended our pulmonary function laboratory and had plethysmographic lung volume measurements pre- and post-bronchodilator (salbutamol). COPD was likely the predominant diagnosis but patients with asthma may have been included. We studied 2,265 subjects (61% male), age 65 ± 9 years (mean ± SD) with a post-bronchodilator FEV(1)/FVC <0.70. We examined relationships between indices of airway obstruction and lung hyperinflation, and measured responses to bronchodilation across subgroups stratified by GOLD criteria. In GOLD stage I, vital capacity (VC) and inspiratory capacity (IC) were in the normal range; pre-bronchodilator residual volume (RV), functional residual capacity (FRC) and specific airway resistance were increased to 135%, 119% and 250% of predicted, respectively. For the group as a whole, RV and FRC increased exponentially as FEV(1) decreased, while VC and IC decreased linearly. Regardless of baseline FEV(1), the most consistent improvement following bronchodilation was RV reduction, in terms of magnitude and responder rate. In conclusion, increases (above normal) in airway resistance and plethysmographic lung volumes were found in those with only minor airway obstruction. Indices of lung hyperinflation increased exponentially as airway obstruction worsened. Those with the greatest resting lung hyperinflation showed the largest bronchodilator-induced volume deflation effects. Reduced air trapping was the predominant response to acute bronchodilation across severity subgroups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21166631     DOI: 10.3109/15412555.2010.528087

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  26 in total

1.  Not all measures of hyperinflation are created equal: lung structure and clinical correlates of gas trapping and hyperexpansion in COPD: the Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study.

Authors:  Benjamin M Smith; Eric A Hoffman; Robert C Basner; Steven M Kawut; Ravi Kalhan; R Graham Barr
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

Review 2.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

Review 3.  New insights into the pathophysiology of mild chronic obstructive pulmonary disease.

Authors:  Jordan A Guenette
Journal:  Can Respir J       Date:  2014 Jan-Feb       Impact factor: 2.409

Review 4.  Pulmonary function testing in COPD: looking beyond the curtain of FEV1.

Authors:  Sotirios Kakavas; Ourania S Kotsiou; Fotis Perlikos; Maria Mermiri; Georgios Mavrovounis; Konstantinos Gourgoulianis; Ioannis Pantazopoulos
Journal:  NPJ Prim Care Respir Med       Date:  2021-05-07       Impact factor: 2.871

5.  A New Bronchodilator Response Grading Strategy Identifies Distinct Patient Populations.

Authors:  James E Hansen; Asli G Dilektasli; Janos Porszasz; William W Stringer; Youngju Pak; Harry B Rossiter; Richard Casaburi
Journal:  Ann Am Thorac Soc       Date:  2019-12

6.  Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease.

Authors:  Roberta Pisi; Marina Aiello; Andrea Zanini; Panagiota Tzani; Davide Paleari; Emilio Marangio; Antonio Spanevello; Gabriele Nicolini; Alfredo Chetta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-19

7.  Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease.

Authors:  Philippe Gagnon; Richard Casaburi; Didier Saey; Janos Porszasz; Steeve Provencher; Julie Milot; Jean Bourbeau; Denis E O'Donnell; François Maltais
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

8.  Airways resistance and specific conductance for the diagnosis of obstructive airways diseases.

Authors:  Marko Topalovic; Eric Derom; Christian R Osadnik; Thierry Troosters; Marc Decramer; Wim Janssens
Journal:  Respir Res       Date:  2015-07-22

9.  Relationships between values of antibodies to several connective tissue disease autoantigens and pulmonary function in a Japanese general population: the Takahata study.

Authors:  Hiroshi Nakano; Yoko Shibata; Sumito Inoue; Akira Igarashi; Keiko Yamauchi; Shuichi Abe; Masamichi Sato; Yasuko Aida; Keiko Nunomiya; Tomomi Kimura; Takako Nemoto; Tetsu Watanabe; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

10.  Flow-Volume Parameters in COPD Related to Extended Measurements of Lung Volume, Diffusion, and Resistance.

Authors:  Linnea Jarenbäck; Jaro Ankerst; Leif Bjermer; Ellen Tufvesson
Journal:  Pulm Med       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.